126P Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Annals of Oncology(2022)
Abstract
FOLFOX (5-fluorouracil, l-leucovorin and oxaliplatin [L-OHP]) is one of the treatment options for patients (pts) with advanced esophageal squamous cell carcinoma (aESCC). Because it is suggested that L-OHP showed activity in pts resistant to Cisplatin (CDDP), we evaluated the efficacy and safety of FOLFOX in pts who received prior CDDP-containing regimen.
MoreTranslated text
Key words
late line folfox therapy,squamous cell carcinoma,cisplatin-based,multi-institutional
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined